Fong Debra, Ullah Md Mahbub, Lal Jaswini G, Abdelkader Amany, Ow Connie P C, Hilliard Lucinda M, Ricardo Sharon D, Kelly Darren J, Evans Roger G
Biomedicine Discovery Institute and Department of Physiology, Monash University, Clayton, Melbourne, Vic., Australia.
Biomedicine Discovery Institute and Department of Anatomy and Developmental Biology, Monash University, Clayton, Melbourne, Vic., Australia.
Clin Exp Pharmacol Physiol. 2016 Oct;43(10):896-905. doi: 10.1111/1440-1681.12621.
We determined whether adenine-induced chronic kidney disease (CKD) in rats is associated with renal tissue hypoxia. Adenine (100 mg) or its vehicle was administered to male Sprague-Dawley rats, daily by oral gavage, over a 15-day period. Renal function was assessed before, and 7 and 14 days after, adenine treatment commenced, by collection of a 24-hour urine sample and a blood sample from the tail vein. On day 15, arterial pressure was measured in conscious rats via the tail artery. Renal tissue hypoxia was then assessed by pimonidazole adduct immunohistochemistry and fibrosis was assessed by staining tissue with picrosirius red and Masson's trichrome. CKD was evident within 7 days of commencing adenine treatment, as demonstrated by increased urinary albumin to creatinine ratio (30 ± 12-fold). By day 14 of adenine treatment plasma creatinine concentration was more than 7-fold greater, and plasma urea more than 5-fold greater, than their baseline levels. On day 15, adenine-treated rats had slightly elevated mean arterial pressure (8 mmHg), anaemia and renomegaly. Kidneys of adenine-treated rats were characterised by the presence of tubular casts, dilated tubules, expansion of the interstitial space, accumulation of collagen, and tubulointerstitial hypoxia. Pimonidazole staining (hypoxia) co-localised with fibrosis and was present in both patent and occluded tubules. We conclude that renal tissue hypoxia develops rapidly in adenine-induced CKD. This model, therefore, should prove useful for examination of the temporal and spatial relationships between tubulointerstitial hypoxia and the development of CKD, and thus the testing of the 'chronic hypoxia hypothesis'.
我们确定了大鼠腺嘌呤诱导的慢性肾脏病(CKD)是否与肾组织缺氧有关。将腺嘌呤(100毫克)或其赋形剂通过口服灌胃每日给予雄性Sprague-Dawley大鼠,持续15天。在腺嘌呤治疗开始前、治疗7天和14天后,通过收集24小时尿液样本和尾静脉血样来评估肾功能。在第15天,通过尾动脉测量清醒大鼠的动脉血压。然后通过匹莫硝唑加合物免疫组织化学评估肾组织缺氧情况,并用天狼星红和Masson三色染色法评估纤维化情况。腺嘌呤治疗开始7天内CKD明显,尿白蛋白与肌酐比值升高(30±12倍)即可证明。到腺嘌呤治疗第14天时,血浆肌酐浓度比基线水平高出7倍多,血浆尿素比基线水平高出5倍多。在第15天,接受腺嘌呤治疗的大鼠平均动脉压略有升高(8mmHg),出现贫血和肾肿大。接受腺嘌呤治疗的大鼠肾脏的特征是存在肾小管管型、肾小管扩张、间质间隙扩大、胶原积累和肾小管间质缺氧。匹莫硝唑染色(缺氧)与纤维化共定位,在开放和阻塞的肾小管中均有出现。我们得出结论,在腺嘌呤诱导的CKD中肾组织缺氧迅速发展。因此,该模型应有助于研究肾小管间质缺氧与CKD发展之间的时间和空间关系,从而验证“慢性缺氧假说”。